Hartford Investment Management Co. Sells 118 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Hartford Investment Management Co. decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,058 shares of the company’s stock after selling 118 shares during the period. Hartford Investment Management Co.’s holdings in IDEXX Laboratories were worth $2,091,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. Creative Planning raised its holdings in IDEXX Laboratories by 2.6% during the 3rd quarter. Creative Planning now owns 24,436 shares of the company’s stock valued at $12,346,000 after acquiring an additional 614 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of IDEXX Laboratories by 19.0% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 3,306 shares of the company’s stock valued at $1,670,000 after purchasing an additional 529 shares during the period. Bleakley Financial Group LLC lifted its holdings in IDEXX Laboratories by 1.4% during the 3rd quarter. Bleakley Financial Group LLC now owns 2,861 shares of the company’s stock worth $1,445,000 after purchasing an additional 39 shares in the last quarter. Marshall Financial Group LLC boosted its stake in IDEXX Laboratories by 1.6% in the 3rd quarter. Marshall Financial Group LLC now owns 1,884 shares of the company’s stock worth $952,000 after purchasing an additional 30 shares during the period. Finally, Cardinal Capital Management grew its holdings in IDEXX Laboratories by 0.7% during the 3rd quarter. Cardinal Capital Management now owns 13,919 shares of the company’s stock valued at $7,032,000 after buying an additional 93 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Barclays increased their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 in the last quarter. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Trading Up 0.5 %

Shares of IDXX stock opened at $459.76 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market cap of $37.65 billion, a P/E ratio of 43.09, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The business has a 50-day moving average price of $430.12 and a two-hundred day moving average price of $453.26. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.